GenFleet Therapeutics announced the first patient with metastatic sigmoid adenocarcinoma has been dosed in a Phase Ib/II trial of GFH018 in combination with toripalimab as part of global multi-center clinical research. There are broad indications for GFH018 in treating solid tumors with lower response rates to PD-1 inhibitors.
[GenFleet Therapeutics]
7992332
{7992332:BBBBBBBB}
apa
50
1
168195
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
